Nonviral Approaches Satisfying Various Requirements for Effective in Vivo Gene Therapy.
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Development of an efficient method of gene introduction to target cells is the key issue in treating genetic and acquired diseases by in vivo gene therapy. Although various nonviral approaches have been developed, any method needs to be optimized in terms of the target disease and transgene product. The most important information required is (i) target cell-specificity of gene transfer, (ii) efficiency, (iii) duration of transgene expression, and (iv) the number of transfected cells following in vivo application of a vector. These characteristics are determined by the properties of the vector used, as well as the route of its administration, biodistribution, interaction with biological components and the nature of the target cells. Cell-specific gene transfer can be achieved by controlling the tissue disposition of plasmid DNA (pDNA), although the interaction of the pDNA complex with biological components might limit the specificity. Various approaches have been reported to increase the efficiency of transgene expression, from cationic lipids/polymers to physical stimuli, but some of those are ineffective under in vivo conditions. The duration of transgene expression is a complex function involving variables including the cell type, transfection method, and plasmid construct. Immune response often reduces the level and duration of transgene expression. In addition, the number of transfected cells is important, especially in cases in which the therapeutic protein localizes within the target cells. Successful clinical application of nonviral gene delivery methods rely on the development of such methods optimized for a particular target disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Direct Gene Transfer into Mouse Muscle in Vivo
Wolff, J. A., Malone, R. W., Williams, P., Chong, W., Acsadi, G., Jani, A., & Felgner, P. L. (1990) · Science · doi:10.1126/science.1690918 · Cited by 4,173
CpG motifs in bacterial DNA trigger direct B-cell activation
Krieg, A. M., Yi, A.-K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A., & Klinman, D. M. (1995) · Nature · doi:10.1038/374546a0 · Cited by 3,508
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Optimization of Plasmid Vectors for High-Level Expression in Lung Epithelial Cells
Yew, N. S., Wysokenski, D. M., Wang, K. X., Ziegler, R. J., Marshall, J., McNeilly, D., Cherry, M., Osburn, W., & Cheng, S. H. (1997) · Human Gene Therapy · doi:10.1089/hum.1997.8.5-575 · Cited by 113
Gene therapy for the hemophilias
Kay, M. A., & High, K. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.18.9973 · Cited by 96
Overexpression of γ-Sarcoglycan Induces Severe Muscular Dystrophy
Zhu, X., Hadhazy, M., Groh, M. E., Wheeler, M. T., Wollmann, R., & McNally, E. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m101877200 · Cited by 56
Cited by
Nonviral Vectors in the New Millennium: Delivery Barriers in Gene Transfer
Nishikawa, M., & Huang, L. (2001) · Human Gene Therapy · doi:10.1089/104303401750195836 · Cited by 574
Self-citationYORK, A., KIRKLAND, S., & MCCORMICK, C. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2008.02.006 · Cited by 349
Chitosan conjugated DNA nanoparticles in gene therapy
Jayakumar, R., Chennazhi, K. P., Muzzarelli, R. A. A., Tamura, H., Nair, S. V., & Selvamurugan, N. (2010) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2009.08.026 · Cited by 302
Vaccination with Messenger RNA (mRNA)
Pascolo, S. (2008) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-540-72167-3_11 · Cited by 126
“Other sites than the skeletal muscle can be used for in vivo gene delivery using naked nucleic acids: skin, liver, and heart muscle, for example; review by Nishikawa ( Nishikawa and Hashida, 2002 ).”
BackgroundNon-viral strategies for ocular gene delivery
Oliveira, A. V., Rosa da Costa, A. M., & Silva, G. A. (2017) · Materials Science and Engineering: C · doi:10.1016/j.msec.2017.04.068 · Cited by 80
“[7] One of the major drawbacks of systemic administration for ocular purposes is that only 1–2% of the administered drugs reach the vitreous.”
BackgroundInfluential
Metadata
- Authors
- Nishikawa, M., & Hashida, M.
- Venue
- Biological and Pharmaceutical Bulletin
- Publisher
- Pharmaceutical Society of Japan
- Published
- 2002
- Volume
- 25
- Issue
- 3
- Pages
- 275-283
- ISSN
- 0918-6158 (ISSN-L)
- 1347-5215
- OpenAlex
- W2058067959
- Cited by
- 100
- References
- 6
- FWCI
- 2.38
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nonviral Approaches Satisfying Various Requirements for Effective in Vivo Gene Therapy. https://app.cochat.ai/papers/10.1248/bpb.25.275
- The paper
- Nishikawa, M., & Hashida, M. (2002). Nonviral Approaches Satisfying Various Requirements for Effective in Vivo Gene Therapy. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.25.275
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.